Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. decreased its position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 42.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,187 shares of the company's stock after selling 33,527 shares during the period. Envestnet Asset Management Inc.'s holdings in Henry Schein were worth $3,196,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its holdings in shares of Henry Schein by 274.6% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company's stock worth $32,000 after purchasing an additional 335 shares during the period. Venturi Wealth Management LLC lifted its position in Henry Schein by 3,347.1% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the company's stock valued at $41,000 after purchasing an additional 569 shares during the period. Quent Capital LLC boosted its holdings in Henry Schein by 91.2% in the fourth quarter. Quent Capital LLC now owns 677 shares of the company's stock valued at $47,000 after purchasing an additional 323 shares during the last quarter. Smartleaf Asset Management LLC grew its position in Henry Schein by 23.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock worth $52,000 after purchasing an additional 143 shares during the period. Finally, City State Bank purchased a new position in shares of Henry Schein during the 4th quarter valued at about $55,000. Institutional investors and hedge funds own 96.62% of the company's stock.

Henry Schein Trading Down 1.8 %

Shares of HSIC stock traded down $1.19 on Wednesday, hitting $64.97. 1,059,826 shares of the stock traded hands, compared to its average volume of 1,618,912. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $82.49. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The stock has a market capitalization of $7.96 billion, a PE ratio of 26.74, a PEG ratio of 2.13 and a beta of 0.84. The firm's 50-day moving average price is $68.49 and its two-hundred day moving average price is $71.68.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.23 by ($0.04). The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.25 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $0.66 earnings per share. As a group, analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current year.

Insiders Place Their Bets

In other Henry Schein news, CEO Bradford C. Connett sold 4,036 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the transaction, the chief executive officer now owns 62,688 shares in the company, valued at $4,460,251.20. The trade was a 6.05 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Philip A. Laskawy sold 2,604 shares of the firm's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the sale, the director now owns 24,805 shares in the company, valued at approximately $1,762,147.20. This represents a 9.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Bank of America raised Henry Schein from an "underperform" rating to a "buy" rating and boosted their price target for the company from $69.00 to $84.00 in a report on Monday, January 6th. Wells Fargo & Company began coverage on shares of Henry Schein in a research report on Friday, February 14th. They issued an "equal weight" rating and a $80.00 price objective for the company. StockNews.com cut Henry Schein from a "buy" rating to a "hold" rating in a research report on Thursday, April 17th. Jefferies Financial Group upped their price target on Henry Schein from $77.00 to $80.00 and gave the stock a "hold" rating in a report on Thursday, January 23rd. Finally, UBS Group lowered their price target on Henry Schein from $83.00 to $80.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 26th. Six equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Henry Schein presently has an average rating of "Moderate Buy" and an average target price of $80.20.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.